12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

SeHCAT regulatory update

The U.K.'s NICE issued draft guidance concluding there is insufficient evidence to determine whether SeHCAT from General Electric's GE Healthcare unit is a useful and cost effective test for diagnosing bile...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >